Together, these three variants represent 50% (9/18) of all germline deleterious variants found in this series, indicating that it might be cost-effective to test for these founder variants with a specific test prior to tumor screening of the entire coding regions of BRCA1 and BRCA2 by NGS in patients of Portuguese ancestry (Figure 1). Here, BRCA2 is linked to neoplasm.